NEWS HIGHLIGHTS
Published Studies Related to Diprolene (Betamethasone Topical)
Topical betamethasone and hyaluronidase in the treatment of phimosis in boys: a double-blind, randomized, placebo-controlled trial. [2011.05]
PURPOSE: To compare the efficacy of three different formulations containing Betamethasone Valerate versus placebo in the topical treatment of phimosis. As a secondary goal, we compared the outcomes after 30 and 60 days of treatment... CONCLUSIONS: Betamethasone Valerate 0.1%, 0.2% and 0.2% in combination with Hyaluronidase had equally higher results than placebo in the treatment of phimosis in boys from three to ten years-old. Patients initially with partial or no response can reach complete response after 60 days of treatment.
Doxepin cream vs betamethasone cream for treatment of chronic skin lesions due to sulfur mustard. [2011.05]
Oral doxepin was shown to reduce chronic pruritus due to sulfur mustard. The present study compared the effects of topical doxepin 5% with betamethasone 1% for the treatment of pruritus in veterans exposed to sulfur mustard...
Significant one week efficacy of a calcipotriol plus betamethasone dipropionate scalp formulation. [2011.01]
BACKGROUND: A two-compound scalp formulation containing calcipotriol (50 mug/g) and betamethasone (0.5mg/g; as dipropionate) (Xamiol, Taclonex Scalp) has been shown to be an effective and safe treatment for scalp psoriasis. OBJECTIVE: The aim of this study was to investigate the clinical efficacy of the two-compound scalp formulation after 1 week of treatment...
Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. [2011]
The aim of this study was to evaluate the pharmacokinetic profiles of betamethasone (BOH, CAS 378-44-9) and betamethasone 17-monopropionate (B17P), the active metabolites of betamethasone phosphate (BSP) and betamethasone dipropionate (BDP), respectively, after administration of betamethasone i.m...
Topical betamethasone and hyaluronidase in the treatment of phimosis in boys: a
double-blind, randomized, placebo-controlled trial. [2011]
secondary goal, we compared the outcomes after 30 and 60 days of treatment... CONCLUSIONS: Betamethasone Valerate 0.1%, 0.2% and 0.2% in combination with
Clinical Trials Related to Diprolene (Betamethasone Topical)
Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4) [Recruiting]
This is a parallel-group, randomized, active-controlled, double-blind, Phase 4 trial
comparing three creams in the treatment of impetiginous eczema:
- Arm A: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole and gentamicin
sulfate)
- Arm B: Combination of betamethasone diproprionate cream and gentamicin sulfate cream
- Arm C: Betamethasone diproprionate cream
At 7 sites, in Portugal, a total of 207 subjects will be randomized using a 1: 1:1
randomization ratio to receive one of the three possible treatments for a maximum period of
28 days or until 5 days after total remission of the signs and symptoms, but never more than
28 days. Assessments will be made of level of improvement of the target area in each
treatment group, number of days for total remission, and safety profile.
Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis [Not yet recruiting]
Topical corticosteroids are largely used in dermatology. The major problem related to their
use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and
antiproliferative) may lead to adverse events. Conditions sensitive to corticosteroids
require formulations with mild to moderate potency while high-potency corticosteroids era
required in less responsive conditions. The aim of the present study is to compare the
safety and efficacy of prednisolone acetate 0. 5% cream (mild-potency non-fluoridated
corticosteroid) versus betamethasone valerate 0. 1% cream (high-potency fluoridated
corticosteroid) in the treatment of mild to moderate cortisosensitive dermatosis (atopic
dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis). The study hypothesis
is that 0. 5% prednisolone cream will be as effective as 0. 1% betamethasone cream and will be
an alternative option to treat corticosensitive dermatosis in body areas where the use of
fluoridated corticosteroids is contraindicated, such as the face.
Efficacy and Safety of Calcipotriene/Betamethasone Gel/Ointment in Psoriasis [Completed]
Patients will receive either a gel containing both calcipotriene plus betamethasone or gel
with no active ingredients as treatment for their scalp psoriasis for 8 weeks. After this
time all patients will receive the gel containing both calcipotriene and betamethasone for 44
weeks. In addition, patients will receive an ointment containing both calcipotriene plus
betamethasone as treatment for their psoriasis of the trunk and limbs for 52 weeks.
The objective is to study the short-term efficacy of the gel, and the short and long-term
safety of the gel and the ointment.
Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section [Recruiting]
This is a randomized, multicenter, double blind, placebo controlled trial of betamethasone
versus a placebo given prior to the mothers at term and near term gestation (>34 and <40
weeks of gestation) who are scheduled to undergo a planned Cesarean section. The study
design is to determine the efficacy and safety of betamethasone in the prevention of
breathing problems commonly seen in this population.
In infants born by elective Cesarean section, it is hypothesized that antenatal
betamethasone treatment will reduce the risk of neonatal intensive care unit (NICU)
admission from 11% to 8% and/or oxygen therapy +/- positive pressure ventilation (PPV) for
>30 minutes from 4. 5% to 2. 5%.
Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus [Completed]
Discoid lupus erythematosus lesions are commonly treated with corticosteroids, but
corticosteroids may induce side effects such as thinning of the skin or scarring. Therefore,
an alternative medication with the same efficacy, but without the side-effects is sought
after.
Pimecrolimus is a newer drug specially designed to treat inflammatory diseases of skin. Its
efficacy in treating discoid lupus erythematosus has not been studied extensively yet.
However studies performed till now show promising results. Long-term topical use of this
medication has not shown any serious side-effects in other skin diseases.
In this study we aimed at comparing pimecrolimus efficacy with that of a common therapeutic
choice, betamethasone valerate 0. 1% cream, to see if pimecrolimus can be used as an
alternative medication in treating discoid lupus erythematosus.
|
